Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Mallinckrodt Plc (NYSE:MNK)

74.92
Delayed Data
As of Aug 26
 -0.32 / -0.43%
Today’s Change
50.90
Today|||52-Week Range
90.64
+0.39%
Year-to-Date
Stock Market News for August 26, 2016
Aug 26 / Zacks.com - Paid Partner Content
Mallinckrodt's Top Drug Could Go the Way of EpiPen
Aug 25 / TheStreet.com - Paid Partner Content
Mallinckrodt DMD Drug Gets Fast Track Status in the U.S.
Aug 26 / Zacks.com - Paid Partner Content
Mallinckrodt (MNK) Stock Climbs on Nuclear Imaging Business Sale
Aug 24 / TheStreet.com - Paid Partner Content
Mallinckrodt Could Be Next in Spotlight Thanks to EpiPen Scrutiny
Aug 25 / TheStreet.com - Paid Partner Content
Swiss Generics Manufacturer Has Strong 1st Half of Year
Aug 22 / GuruFocus News - Paid Partner Content
Mallinckrodt to Divest Nuclear Imaging Business for $690M
Aug 25 / Zacks.com - Paid Partner Content